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bjectives We performed this study to investigate the vascular response in early period after
otarolimus-eluting stent (ZES) (Endeavor Sprint, Medtronic CardioVascular, Minneapolis, Minnesota)
mplantation.
ackground The ZES has different characteristics, with biocompatible polymer and rapid drug-
lution, compared with the ﬁrst-generation drug-eluting stents (DES).
ethods The ENDEAVOR OCT (Evaluation in 3 Months Duration of Neointimal Coverage after
otarolimus-Eluting Stent Implantation by Optical Coherence Tomography) trial is a prospective,
ingle-center study evaluating vascular healing patterns with optical coherence tomography (OCT) at
months after stent implantation. A total of 31 ZES in 30 patients underwent serial OCT at immedi-
te post-intervention and 3 months. Neointimal growth and malapposition were analyzed at each
tent strut of cross-sectional OCT images with 0.5-mm intervals.
esults The incidence of malapposition at post-intervention and 3 months was 6.0% and 0.2%,
espectively. However, late acquired malapposition was not detected at 3 months. Of 31 stents,
7 stents (87.1%) were covered completely with neointima, but the remaining 4 stents had 2 (0.8%),
(0.9%), 4 (1.2%), and 6 (1.4%) uncovered struts. Overall mean percentage of covered stent struts
as 99.9  0.4%. This ﬁnding was consistent among groups with acute coronary syndrome and sta-
le angina pectoris (99.9  0.3% vs. 99.9  0.4%, p  0.92). Intracoronary thrombus was docu-
ented in 1 stent (3.2%) among 31 stents.
onclusions Most of the stent struts were covered with neointima, and late acquired malapposition
as not found at 3 months after ZES implantation. Therefore, the current study demonstrated that
ES might have a favorable in vivo vascular response at 3 months after stent implantation. (Evalua-
ion of Zotarolimus Eluting Stent at 3 Months Using Optical Coherence Tomography [ENDEAVOR
CT]; NCT00815139) (J Am Coll Cardiol Intv 2009;2:1240–7) © 2009 by the American College of
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1241he first-generation drug-eluting stents (DES) remarkably
educed the rate of in-stent restenosis and subsequent target
esion revascularization. However, excessive inhibition of
eointimal formation caused delayed vascular healing with
ncomplete endothelialization, which has been associated
ith an increased risk of late stent thrombosis (LST) (1,2).
athology studies also demonstrated that incomplete endo-
helialization as well as partial neointimal coverage were
mportant risk factors for LST after DES implantation
3,4).
Second-generation DES have been developed to over-
ome safety concerns and maintain the efficacy similar to
rst generation DES. Zotarolimus-eluting stents (ZES)
ave a cobalt chromium-based thin-strut stent with a
hosphorylcholine biocompatible polymer and shorter
rug-elution time within 2 weeks (5). Recent studies re-
orted that ZES was associated with a higher rate of
eointimal coverage at 8 months than sirolimus-eluting
tents (SES) on intravascular ultrasound (IVUS) and had as
imilar pattern of neointimal coverage as that of bare-metal
tents (BMS) on angioscopy (6,7). In the randomized
linical trial that compared ZES with SES or paclitaxel-
luting stent, most of the stent struts in ZES were covered
y neointima on optical coherence tomography (OCT) at 6
onths after implantation (8).
It has been proposed, on the basis of previous findings,
hat favorable arterial healing with early endothelialization
ould be achieved in ZES (6). However, there have been no
CT data regarding stent strut coverage and malapposition
f ZES in the early period. Therefore, the present study was
esigned to evaluate the vascular response of neointima
ormation and malapposition at 3 months after ZES im-
lantation with serial OCT evaluation.
ethods
tudy design and patients. The ENDEAVOR OCT (Eval-
ation in 3 Months Duration of Neointimal Coverage after
otarolimus-Eluting Stent Implantation by Optical Coher-
nce Tomography) trial was a prospective, single-center
tudy to investigate the vascular healing pattern of the ZES
Endeavor Sprint, Medtronic CardioVascular, Minneapolis,
innesota) with OCT at 3 months after stent implantation.
The study protocol of the current report was approved by
he Institutional Review Board of Yonsei University College
f Medicine, and written consent was obtained from all
atients before inclusion.
From February 2008 to August 2008, 30 patients (15
cute coronary syndrome [ACS] and 15 stable angina
ectoris [SAP]) suitable for an OCT procedure and who
onsented to the study protocol were enrolled in this study.
atients were eligible for the study if they had: 1) a de novo
esion with 50% diameter stenosis related to myocardial
schemia with objective study or 70% diameter stenosis; Ind 2) a native coronary artery with a reference vessel
iameter (RVD) between 2.5 and 3.5 mm that could be
overed by a single stent. The exclusion criteria were: 1)
ignificant left main disease; 2) bifurcation lesion requiring
stents; 3) apparent congestive heart failure or ejection
raction 30%; 4) an allergy to antiplatelet agents or
ontrast dye; 5) known renal failure with baseline creatinine
2.0 mg/dl; 6) life expectancy1 year; 7) lesions unsuitable
or OCT (proximal vessel size3.5 mm or proximal lesions
15 mm from the ostium of each artery); 8) overlapping
tent; and 9) treatment with other DES at same or other
essels.
tudy procedure. After enrollment, all patients were treated
ith a ZES, and target lesions were evaluated with IVUS
nd OCT immediately after and
months after stent implanta-
ion. Before intervention, all pa-
ients with ACS were pre-
reated with 300 mg or 600 mg
oading dose of clopidogrel in
ase of myocardial infarction
MI) requiring percutaneous
oronary intervention (PCI)
ithin 6 h, and patients with
AP received clopidogrel 75 mg
or at least 5 days before PCI.
fter the intervention, all pa-
ients received dual antiplatelet
herapy (DAT) (aspirin 100 mg
nd clopidogrel 75 mg daily) for
t least 3 months.
oronary angiography. Quanti-
ative coronary angiography was
erformed with a computerized
dge-detection quantitative cor-
nary angiographic system
CASS system, Pie Medical In-
truments, Maastricht, the
etherlands) by a single individ-
al blinded to the patient’s in-
ormation. The minimal lumen diameter and RVD of
reated coronary segments on baseline angiogram were
etermined in the view that demonstrated lesions to be the
ost severe and not foreshortened. Post-procedure and
ollow-up angiograms were evaluated in the same
rojection.
VUS image protocol and analysis. The IVUS assessments
ere performed with a commercially available system (Bos-
on Scientific, Natick, Massachusetts) after intracoronary
dministration of 200 g of nitroglycerin. Motorized trans-
ucer pullback permitted cross-sectional area measurements
t 0.5-mm axial increments from 5-mm distal to proximal
eference segments including the length of the stent. The
Abbreviations and
Acronyms
ACS  acute coronary
syndrome
DAT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
IVUS  intravascular
ultrasound
LST  late stent thrombosis
MI  myocardial infarction
NIH  neointimal hyperplasia
OCT  optical coherence
tomography
PCI  percutaneous
coronary intervention
RVD  reference vessel
diameter
SAP  stable angina
pectoris
SES  sirolimus-eluting
stents(s)
ZES  zotarolimus-eluting
stent(s)VUS images were independently analyzed with an offline
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1242nalysis index system (Echoplaque 2, INDEC Systems,
nc., Mountain View, California) by an independent single
ndividual. The reference segment was the most visibly
ormal cross section (largest lumen with least plaque bur-
en) within 5 mm proximal or distal to the lesion. External
lastic membrane cross-sectional area, lumen cross-sectional
rea at reference segment, and minimal lumen area at stent
egment were determined both after intervention and 3
onths later.
Neointimal volume (NV) was calculated as stent volume
SV) minus lumen volume (LV), and NV index was the
alue of NV divided by stent length. The percent neointimal
bstruction was calculated as: NV divided by SV  100.
he percent neointimal coverage was defined as the mea-
urement of circumferential stent length covered with neo-
ntima divided by stent perimeter at every 0.5-mm cross-
ectional image throughout the stented segment (6).
CT image protocol and analysis. The IVUS was conducted
efore OCT in all cases to evaluate each lesion for the
ositioning of balloon occlusion and vessel size. A time domain
2 OCT system (M2 Cardiology Imaging System, LightLab
maging, Inc., Westford, Massachusetts) combined with a
.014-inch wire-tip imaging catheter (ImageWire, LightLab
maging, Inc.) was used in this study. During image acquisi-
ion, the occlusion balloon (Helios, Avantec Vascular Corp.,
unnyvale, California) was inflated to 0.4 to 0.6 atm, and
inger’s lactate was infused at 0.5 to 1.0 ml/s. The imaging
ire was automatically pulled back from distal to proximal
t 1 mm/s. The OCT analysis was independently performed
y 2 physicians blinded to the patient’s information with the
ame method as previous reports (9,10). Cross-sectional
CT images were analyzed at 0.5-mm intervals (every 7 or
frames). Among 1,368 cross sectional images, 133 images
9.8%) at post-intervention and 27 images (2.0%) at the
-month follow-up OCT could not be measured due to the
oor image quality. Strut malapposition was defined as
etachment from the vessel wall 110 m for ZES (11).
hen there was no definite neointima (10 m of neoin-
ima thickness due to axial resolution of current OCT
echnology) over the stent strut, it was defined as an
ncovered strut. A completely covered stent was defined as
stent with all analyzable struts covered with neointima.
tent struts at the level of bifurcation were included in this
nalysis for neointimal coverage but excluded in the analysis
or malapposition. Thrombus was defined as an irregular
ass protruding into the lumen discontinuing or beyond
tent struts with a signal-free shadowing in the OCT image
12).
linical follow-up. All patients received DAT (aspirin and
lopidogrel) for at least 3 months. Death, nonfatal MI,
arget vessel revascularization, and stent thrombosis were
onsidered major cardiac adverse events.
tudy end points. The primary end point of this trial was to
valuate the neointimal coverage of ZES with OCT at 3 lonths after stent implantation. Secondary end points
ere: 1) malapposition rate at immediate post-intervention
nd 3 months after stent implantation with serial OCT; 2)
omparison of the stent strut coverage and malapposition
ate with OCT between ACS and SAP; and 3) comparison
f stent strut coverage and malapposition rate between
CT and IVUS.
tatistical analysis. Results are expressed as a mean  SD
median) or number (percent). Comparisons of categorical
ariables were made with the chi-square test and the Fisher
xact test when the expected frequency was 5. Student t
est or paired t test was used to compare continuous
ariables, and the Mann-Whitney U test was applied if the
istributions were skewed. For OCT analysis in this study,
nterobserver and intraobserver variabilities in measured
istance and area were assessed by evaluation of 20 random
ross-sectional images by 2 independent readers and by the
ame reader at 2 separate time points, respectively. The
ariations between measurements were calculated with the
inear mixed model (1- and 2-way mixed models). The
ntraobserver correlation coefficient of neointimal hyperpla-
ia (NIH) thickness or distance and area between the
ariabilities of the single observer was 0.99 (95% confidence
nterval [CI]: 0.99 to 1.00) and 0.99 (95% CI: 0.99 to 0.99)
ith the 1-way mixed model, respectively, where patient
ffects are random. The inter-observer correlation coeffi-
ient of NIH thickness or distance and area between
ariabilities of 2 observers with the 2-way mixed model,
here patient effects are random and observers effects are
xed, was 0.99 (95% CI: 0.99 to 1.00) and 0.99 (95% CI:
.99 to 1.00), respectively. All analyses were performed
ith the Statistical Analysis System software (version 9.1.3.,
AS Institute, Cary, North Carolina). A p value 0.05 was
onsidered statistically significant.
esults
atient characteristics. Baseline characteristics in the study
opulation are presented in Table 1. The prevalence of
iabetes was 26.7% in all patients, with no difference
etween patients with ACS and SAP. Among patients with
CS, ST-segment elevation MI was present in 3 (20.0%),
on–ST-segment elevation MI was present in 5 (33.3%),
nd unstable angina was present in 9 (46.7%). Mean stent
iameter was 3.0  0.4 (median 3.0) mm in all patients.
aximum balloon inflation pressure was 16.2  1.9 (me-
ian 16.0) atm.
ngiographic results. Angiographic findings are summa-
ized in Table 2. Overall mean RVD was 2.8 0.3 (median
.7) mm and was similar between groups with ACS and
AP. Late loss at the 3-month follow-up was 0.4  0.3
median 0.4) mm without any difference between 2 groups.
VUS ﬁndings. Table 3 summarizes the IVUS data. Minimal
umen diameter immediately after stenting was 5.4  1.5
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1243median 5.0) mm2. On qualitative IVUS analysis, a malap-
osition was detected in 3 stents (9.7%) at post-intervention
nd in 2 stents (6.5%) at 3 months. Late acquired malap-
osition was not detected in ZES at 3 months after stent
mplantation. Approximately 26% of all stent surfaces were
overed with neointima in IVUS analysis without difference
ccording to the clinical presentation (Fig. 1). No thrombus
as detected during serial IVUS examination.
CT ﬁndings. All stents were serially evaluated by OCT
ithout any serious complication during the procedure.
ean neointima thickness at 3 months was 154 m, which
Table 1. Baseline Characteristics
Total
Patients characteristics (n  30)
Age, yrs 62.1 9.1 (62.7)
Male 18 (60%)
Hypertension 15 (50.0%)
Diabetes mellitus 9 (26.7%)
Hyperlipidemia 18 (60.0%)
Current smoking 6 (20.0%)
Previous MI 0 (0.0%)
Chronic total occlusion 0 (0.0%)
Lesions characteristics (n  31)
Target vessel
LAD 12 (38.7%)
LCX 8 (25.8%)
RCA 11 (35.5%)
Lesion type
A or B1 13 (41.9%)
B2 or C 18 (58.1%)
Stent diameter (mm) 3.0 0.4 (3.0)
Stent length (mm) 22.0 5.3 (20.0)
Maximal pressure (atm) 16.2 1.9 (16.0)
Values are presented as mean SD (median) or n (%).
ACS acute coronary syndrome; LAD left anterior descending artery; LCX left circumflex ar
Table 2. QCA Findings
Total (n  31)
Pre-PCI
Mean RVD (mm) 2.8 0.3 (2.7)
MLD (mm) 0.8 0.5 (0.9)
Post-PCI
Mean RVD (mm) 2.9 0.3 (3.0)
MLD (mm) 2.7 0.4 (2.6)
Acute gain (mm) 1.9 0.5 (1.8)
Follow-up QCA data at 3 months
Mean RVD (mm) 2.8 0.4 (2.8)
MLD (mm) 2.2 0.4 (2.2)
Late loss (mm) 0.4 0.3 (0.4)
Values are presented as n (%) or mean SD (median).
DS diameter stenosis; MLDminimal lumen diameter; PCI percutaneous coronary intervenin Table 1.esulted in approximately 19% of a neointimal volume
bstruction. However, one-third of neointima over stent
trut was 100 m in NIH thickness. General OCT
ndings are summarized in Table 4. The mean lumen area
as 7.5  1.7 (median 6.9) mm2 at post-intervention and
.6  1.8 (median 6.2) mm2 at 3 months. The incidence of
alapposed struts was 6.0  6.2% (4.5%) at post-
ntervention and significantly decreased to 0.2  1.1 (0%)
ithout any late acquired malapposed struts at 3 months
p 0.001). Stent edge dissection was detected in 14 lesions
45.2%) at the post-intervention but completely disappeared
ACS SAP p Value
(n  15) (n  15)
 8.1 (60.4) 63.1 10.2 (67.4) 0.59
9 (60.0%) 9 (60.0%) 1.00
8 (53.3%) 7 (46.7%) 0.72
3 (20.0%) 6 (40.0%) 0.43
9 (60.0%) 9 (60.0%) 1.00
3 (20.0%) 3 (20.0%) 1.00
0 (0.0%) 0 (0.0%) 1.00
0 (0.0%) 0 (0.0%) 1.00
(n  16) (n  15)
0.04
4 (25.0%) 8 (53.3%)
3 (18.8%) 5 (33.3%)
9 (56.3%) 2 (13.3%)
0.75
7 (43.8%) 6 (40.0%)
9 (56.2%) 9 (60.0%)
 0.3 (3.0) 3.0 0.4 (2.8) 0.10
 4.9 (22.0) 21.9 5.8 (18.0) 0.77
 1.8 (16.0) 16.1 2.1 (16.0) 0.71
myocardial infarction; RCA right coronary artery; SAP stable angina pectoris.
ACS (n  16) SAP (n  15) p Value
2.8 0.3 (2.9) 2.7 0.3 (2.7) 0.21
0.7 0.5 (0.7) 0.9 0.5 (0.9) 0.23
3.0 0.3 (3.0) 2.8 0.3 (2.9) 0.07
2.7 0.4 (2.7) 2.6 0.3 (2.5) 0.50
2.0 0.5 (2.0) 1.7 0.6 (1.5) 0.09
2.8 0.3 (2.8) 2.7 0.4 (2.7) 0.44
2.3 0.3 (2.3) 2.1 0.4 (2.1) 0.11
0.4 0.3 (0.3) 0.5 0.3 (0.5) 0.29
A quantitative coronary angiography; RVD reference vessel diameter; other abbreviations as61.3
3.1
22.1
16.3tion; QC
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1244n OCT examination after 3 months. Thrombus was
etected in 1 stent (3.2%) at 3 months, although it was
isible in 11 stents (35.5%) at post-intervention.
Representative cases of neointimal coverage over well-
pposed and malapposed struts and struts at the side branch
re shown in Figure 2. Most of the stent struts were covered
ith neointima (99.9  0.4% [100%]) (Fig. 1), and this
nding was comparable between groups with ACS and
AP. Of the 31 stents evaluated, 27 (87.1%) were com-
letely covered with neointima. The remaining 4 partially
Table 3. Intravascular Ultrasound Findings
Total (n  31)
Post-PCI
Reference EEM CSA (mm2) 11.2 2.7 (11.0)
Reference lumen CSA (mm2) 6.9 1.9 (6.4)
MLA at stent segment (mm2) 5.4 1.5 (5.0)
Malapposition at post-PCI 3/31 (9.7%)
Follow-up at 3 months
Reference EEM CSA (mm2) 11.6 3.3 (11.1)
Reference lumen CSA (mm2) 7.1 2.1 (6.3)
MLA at stent segment (mm2) 5.1 1.5 (4.8)
NVI (mm3/mm) 0.5 0.5 (0.3)
NV obstruction (%) 6.8 6.9 (4.4)
Persistent malapposition 2/31 (6.5%)
Late-acquired malapposition 0/31 (0.0%)
Values are presented as mean SD (median) or n (%). Index values were defined as each paramete
CSA cross-sectional area; EEM external elastic membrane; MLAminimal lumen area; NVI
Figure 1. Rate of Neointimal Coverage in Zotarolimus-Eluting Stents at
3-Month Follow-Up
The rate of neointimal coverage was nearly 100% in optical coherence
tomography (OCT) but only 25% in intravascular ultrasound (IVUS). The
percent neointimal coverage was deﬁned as the measurement of circum-
ferential stent length covered with NIH divided by stent perimeter at every
0.5-mm cross-sectional image throughout the stented segment in IVUS (6).
The rate of neointimal coverage is expressed as a mean  SD (median).n
ACS  acute coronary syndrome; SA  stable angina.overed stents had only 2 (0.8%), 4 (0.9%), 4 (1.2%), and 6
1.4%) uncovered struts.
linical outcome. At 3 months, target vessel revasculariza-
ion occurred in 2 patients, but there were no deaths,
onfatal MI, or stent thrombosis during the 3-month
ollow-up period.
iscussion
his is the first study to evaluate the in vivo vascular
esponse at 3 months after ZES implantation with serial
CT examination. This study demonstrated that most of
tent struts were covered with neointima and were well-
pposed in ZES at 3 months.
valuation of neointimal coverage with intravascular imaging
odalities. Neointimal coverage after stent implantation
as been known to prevent LST as found by autopsy study
nd could be a key parameter to guide the optimal duration
f DAT (3). Also, residual thrombi have been reported as
nother parameter responsible for subacute and late ST
13–15). Therefore, the detection of neointima of stents and
hrombi might give important clinical information to be
ble to estimate the risk of LST. However, identifying thin
eointima and thrombus has numerous limitations in the
linical setting. Intravascular ultrasound has been widely
sed to detect neointima after stent implantation, but its
esolution is a critical limitation, because it can only detect
eointima thicker than 100 m (9,16). Angioscopy is a
seful tool to evaluate neointima by providing direct visu-
lization; however, it is not able to generate quantitative
nformation (17). Recently, OCT was introduced as a
igh-resolution image modality with 10 to 20 m of axial
esolution with an infrared light source (18,19). This new
ntravascular imaging tool is able to clearly detect thin
ACS (n  16) SAP (n  15) p Value
11.6 3.0 (11.7) 10.6 2.4 (10.4) 0.29
7.3 2.1 (7.1) 6.4 1.4 (6.2) 0.22
5.5 1.3 (5.2) 5.3 1.8 (4.9) 0.38
1/16 (6.3%) 2/15 (13.3%) 0.60
12.2 3.4 (11.9) 10.9 3.1 (10.1) 0.34
7.4 2.3 (6.4) 6.8 1.8 (6.3) 0.77
5.1 1.3 (4.8) 5.0 1.7 (4.9) 0.60
0.5 0.5 (0.2) 0.5 0.5 (0.4) 0.52
6.8 7.9 (3.5) 6.7 5.8 (6.4) 0.63
1/16 (6.3%) 1/15 (6.7%) 1.00
0/16 (0.0%) 0/15 (0.0%) 1.00
d by stent length.
timal volume index; other abbreviations as in Tables 1 and 2.r divideeointima and provide quantitative information about neo-
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1245ntima. The data from this study showed a large discrepancy
n the rate of neointimal coverage between IVUS and OCT
25.8  22.0% [20.7%] in IVUS vs. 99.9  0.4% [100%] in
CT), although the method of measurement was some-
hat different. The distribution of NIH thickness evaluated
ith OCT might provide an explanation for this finding
proportion of NIH thickness 100 m: 35.4%).
indings at immediate post-intervention and 3-month
ollow-up after ZES implantation. This study demonstrated
hat IVUS and OCT showed a considerable numbers of
tents were malapposed immediately after ZES implanta-
ion, which was similar to that previously observed (6).
nterestingly, any stent edge dissection was not detected in
Table 4. Optical Coherence Tomographic Findings
Total (n  31)
Post-PCI
Lumen area (mm2) 7.5 1.7 (6.9)
Plaque prolapse 29 (93.5%)
Malapposition at post-PCI 6.0 6.2 (4.5)
Stent edge dissection 14 (45.2%)
Presence of thrombi 11 (35.5%)
Follow-up at 3 months
Lumen area (mm2) 6.6 1.8 (6.2)
Neointimal thickness (m) 154 77 (137)
NIH area (%) 18.6 7.9 (16.0)
Persistent malapposition 0.2 1.1 (0)
Late-acquired malapposition 0
Both of malapposed and uncovered strut (%) 0.03 0.1 (0)
Stent edge dissection 0 (0.0%)
Presence of thrombi 1 (3.2%)
Values are presented as mean SD (median) or n (%). Stent malapposition was defined as struts w
NIH neointimal hyperplasia; other abbreviations as in Tables 1 and 2.
Figure 2. Representative Serial Optical Coherence Tomography ImagesNeointima were covered at well-apposed struts (left), malapposed struts (middle), aVUS, but was shown in 14 cases (45.2%) on OCT. No
urther procedures were performed in these cases, because
hey were not associated with flow limitation. Subsequently,
here were no stent edge dissections detected at 3-month
ollow-up OCT.
The first generation of DES yielded significantly lower
ercent neointimal obstruction than BMS (3% to 5% in
ES vs. 8% to 13% in paclitaxel-eluting stent vs. 29% to
5% in BMS) (6,20,21). However, excessive suppression of
eointima increased the concern of ST, because of incom-
lete endothelization during the vascular healing process
fter stent implantation (22). Attention has recently shifted
rom late loss or percent neointimal obstruction to endo-
ACS (n  16) SAP (n  15) p Value
7.6 1.4 (7.3) 7.4 2.0 (6.5) 0.26
16 (100%) 13 (86.7%) 0.86
6.9 8.3 (4.1) 5.0 2.6 (4.8) 0.41
7 (43.8%) 7 (46.2%) 0.87
7 (43.8%) 4 (26.7%) 0.32
6.6 1.9 (6.1) 6.5 1.7 (6.5) 0.91
157 94 (136) 151 56 (142) 0.82
19.0 9.5 (16.4) 18.2 6.1 (16.0) 0.78
0.4 1.6 (0) 0.02 0.1 (0) 0.77
0 0 1.00
0.03 0.1 (0) 0.02 0.09 (0) 1.00
0 (0.0%) 0 (0.0%) 1.00
1 (6.3%) 0 (0.0%) 1.00
chment from the vessel wall110 m for zotarolimus-eluting stent.ith detand struts at bifurcation (right).
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Neointimal Coverage of ZES in OCT at 3 Months
1246helial coverage over the stent strut. To this point, the
resence of a moderate amount of neointimal growth with
ndothelialization is likely a valid solution to avoid in-stent
estenosis and to minimize the risk of ST.
In the current study, several intravascular imaging
odalities were used to evaluate neotintimal coverage. As
entioned previously regarding the resolution according
o the different methods of intravascular imaging, fre-
uencies of detectable neointima were quite different. In
he IVUS examination, Miyazawa et al. (6) reported that
ore than one-half of the ZES struts were covered with
etectable neointima with even distribution, whereas only
0% of SES struts were covered with small but focal
ccumulation at 8 months. This study showed that with
VUS, 25% of stent struts were covered with neointima at
months after ZES implantation. The low rate of
eointimal coverage might be related to inherent limita-
ion in IVUS resolution (100 to 150 m), because the
ean NIH thickness was 150 m at 3 months compared
ith 250 m at 9 months in previous OCT study (11). A
ecent angioscopy study of ZES demonstrated that all
tent struts were covered with grade 2 or 3 of endothe-
ization without detectable thrombus at 8 months after
tent implantation. Several OCT studies reported a
imilar finding in ZES. The ODESSA (Optical coher-
nce tomography in Drug Eluting Stent Safety) trial and
previous study we reported (OCT evaluation at 9 months
n ZES) have shown that ZES had nearly complete neoin-
imal coverage of stent struts at 6 months and 9 months
fter stent implantation, respectively (8,10).
The ZES has different properties compared with other
ES, which includes rapid drug-elution and a biocompat-
ble polymer. Hence, the vascular response might be differ-
nt even in the early period after ZES implantation. The
ollow-up OCT data at 3 months revealed that approxi-
ately 15% of stent struts were uncovered with neointima
n SES, whereas most of the stent struts were covered with
eointima in BMS (17). However, there were no data on
ES in the early period before 6 months. In the current
tudy, most of the stent struts were covered with neointima
ven at 3 months, irrespective of clinical presentations.
herefore, this study provides new information on the time
equired for complete neointimal coverage to occur, with 3
onths being sufficient for a ZES. The question remains as
o whether the neointima coverage of stent struts is preven-
ive for LST, and large randomized trial or registry data
ight be warranted to determine the optimal duration of
AP in ZES.
Although the relationship between late malapposition as
een by IVUS and LST is not well-known, it could be a
oncern for future clinical events after DES implantation.
revious studies have shown a late acquired malapposition
ate of 3% to 13% with SES and 2% to 8% with paclitaxel-
luting stent (23–25). However, the ENDEAVOR III CVUS study reported only 1 case (0.5%) of late acquired
alapposition with the ZES and this study also showed no
ate acquired malapposition for either IVUS or OCT. On
CT evaluation, the total late malapposition rate, including
ersistent and late acquired malapposition, was similar to
MS and low-incidence compared with SES at 3-month
ollow-up when compared with previous studies (1.1% in
MS, and 15.0% in SES vs. 0.2% in ZES in this study)
17). Therefore, this finding suggests that the ZES has
avorable vascular responses in term of stent apposition as
ell as neointimal coverage over stent.
tudy limitations. First, because pre-interventional OCT
valuation was not performed in this study, we cannot assess
he effect of underlying plaque characteristics on the vascular
esponse after ZES implantation. However, because most of
he stent struts were covered with neointima and well-
pposed at 3 months irrespective of clinical presentation, we
elieve that there was little effect of underlying plaque
haracteristics on vascular healing and stent apposition after
ES implantation. Second, this study was a single-center
tudy with a relatively small population and might have a
isk of selection bias. However, over 12,000 stent struts were
valuated for neointimal coverage or malapposition. Also,
e analyzed quantitative coronary angiography, IVUS, and
CT independently. Third, quality evaluation of NIH
ight be important to investigate the risk of future throm-
us formation, but the present study did not clarify the
uality of NIH because the current OCT technology might
ave some limitations to separate fibrin or microthrombi
rom healthy neointima. Fourth, the clinical relevance of
eointimal coverage detected by OCT or IVUS remains
nknown. Finally, OCT analysis was not performed in an
ndependent core laboratory, although inter-observer and
ntra-observer variabilities were assessed to prove the con-
istence and accuracy of measurement.
onclusions
his is the first study to evaluate the vascular healing
esponse with neointimal coverage and malapposition of
ES at 3 months after stent implantation with serial OCT
xamination. This study demonstrated that neointimal cov-
rage was nearly complete and no late acquired malapposi-
ion was detected at 3 months after ZES implantation.
herefore, this study implies that the ZES has a favorable
ascular healing process in the early period after stent
mplantation.
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